Product Browser

Last updated: 2016/12/4

Product Compare

Product Compare Cancel Click this icon to add products to compare list. Select up to 10 products.

Quick Order (Tutorial)

Input Catalog #,
place order here!
Catalog # :
  • Where to buy
  • Choose your location

RARRES3 293T Cell Transient Overexpression Lysate(Denatured)

  • Catalog # : H00005920-T01
  • Visit Frequency :
  • Countries :
  • Specification
  • Transfected Cell Line:
  • 293T
  • Plasmid:
  • pCMV-RARRES3 full-length
  • Host:
  • Human
  • Theoretical MW (kDa):
  • 18.15
  • Quality Control Testing:
  • Transient overexpression cell lysate was tested with Anti-RARRES3 antibody (H00005920-B01) by Western Blots.
    SDS-PAGE Gel
    QC Testing of H00005920-T01
    RARRES3 transfected lysate
    Western Blot
    QC Testing of H00005920-T01
    Lane 1: RARRES3 transfected lysate ( 18.15 KDa).
    Lane 2: Non-transfected lysate.
  • Storage Buffer:
  • 1X Sample Buffer (50 mM Tris-HCl, 2% SDS, 10% glycerol, 300 mM 2-mercaptoethanol, 0.01% Bromophenol blue)
  • Storage Instruction:
  • Store at -80°C. Aliquot to avoid repeated freezing and thawing.
  • Applications
  • Western Blot
  • Application Image
  • Western Blot
  • Gene Information
  • Entrez GeneID:
  • 5920
  • Gene Name:
  • RARRES3
  • Gene Alias:
  • HRASLS4,MGC8906,RIG1,TIG3
  • Gene Description:
  • retinoic acid receptor responder (tazarotene induced) 3
  • Gene Summary:
  • Retinoids exert biologic effects such as potent growth inhibitory and cell differentiation activities and are used in the treatment of hyperproliferative dermatological diseases. These effects are mediated by specific nuclear receptor proteins that are members of the steroid and thyroid hormone receptor superfamily of transcriptional regulators. RARRES1, RARRES2, and RARRES3 are genes whose expression is upregulated by the synthetic retinoid tazarotene. RARRES3 is thought act as a tumor suppressor or growth regulator. [provided by RefSeq
  • Other Designations:
  • retinoic acid-inducible gene 1
  • RSS
  • YouTube
  • Linkedin
  • Facebook